Low-dose dopexamine in patients undergoing hemihepatectomy: an evaluation of effects on reduction of hepatic dysfunction and ischaemic liver injury

BACKGROUND: Hepatic dysfunction is a common problem in patients after hemihepatectomy. Treatment with low-dose dopamine has been shown to be beneficial in hemihepatectomy patients. We hypothesized that dopexamine, a synthetic vasoactive catecholamine, due to its specific pharmocodynamic profile may be more effective in reducing hidden ischaemic episodes in the hepato-splanchnic region during and after temporary total cross-clamping of hepatic inflow in these patients. METHODS: The effects of low-dose dopexamine on hepatic venous haemoglobin oxygen saturation (ShvO2), hepatic venous lactate level, monoethylglycinxylid (MEGX) formation, hepatic synthetic function and indicators for hepatic cell damage were studied during hemihepatectomy and for 16 h postoperatively in hemihepatectomy patients and compared to those of low-dose dopamine. In a prospective, double-blind clinical study 20 patients received randomly either dopexamine (DPX) 0.5 microg kg(-1) min(-1) (n=10) or dopamine (DO) 2.5 microg kg(-1) min(-1) (n= 10). Infusions were started after induction of anaesthesia and continued 16 h postoperatively. Hepatic vein, radial and pulmonary artery were catheterized. Measurements were carried out after induction of anaesthesia, after total cross-clamping of hepatic inflow, and at 2 h and 16 h postoperatively. RESULTS: There were no differences in systemic haemodynamics, oxygenation, ShvO2, serum aminotransferases or MEGX levels between the groups. At 16 h postoperatively prothrombin and antithrombin III levels were significantly lower while hepatic venous lactate was significantly higher in the DPX group compared to the DO group. CONCLUSION: In patients undergoing hemihepatectomy, we could not reveal superior hepatoprotective effects of low-dose dopexamine compared to low-dose dopamine.     

肝部分切除治疗肝内胆管结石疗效分析

目的　探讨肝段切除与胆管切开取石术治疗肝内结石的效果。方法　对 98例肝内胆管结石进行回顾性分析 ,按治疗方式分A组采用肝段切除为主的联合手术 4 8例 ,B组采用胆管切开为主的联合手术 5 0例 ,观察两组治疗效果及并发症发生率。结果　A组较B组术后残石率 ,结石复发率 ,再手术率均低 (P <0 .0 5 ) ,有显著性差异。结论　肝段切除为主的联合手术能有效降低肝内胆管结石术后残石发生、结石复发和再手术率 ,是当前治疗肝内胆管结石的首选术式     

肝部分切除术对大鼠门静脉途径肝细胞转基因效率的影响

目的 :探讨肝部分切除术对大鼠肝细胞门静脉途径转基因效率的影响。方法 :Wistar大鼠分 4组 ,每组 5只 :A1组 :30 %切肝并于门静脉注射脂质体—质粒 DNA混合物 (lipofectamine- p EGFP- N1DNA complexes,lipoplexes) ;A2组 :30 %切肝并于门静脉注射生理盐水 (NS) ;B1组 :70 %切肝并于门静脉注射 lipoplexes;B2组 :70 %切肝并于门静脉注射 NS。转染后 15 d均以胶原酶消化、Percoll液梯度离心法获取纯化肝细胞悬液 ;以 NS组为对照并以 GFP为荧光标记物 ,用流式细胞仪 (flow cytometry,FCM)分析各实验组肝细胞的转染率。结果 :A1组和 B1组的平均转染率分别为 :(1.12± 0 .5 0 ) %、(3.91± 1.6 8) % ;B1组明显高于 A1组 (P<0 .0 5 )。结论 :与 30 %肝部分切除术相比 ,70%切肝可显著提高大鼠肝细胞门静脉途径转基因的效率     

术后后装放疗、吉西他滨化疗治疗原发性肝癌(英文)

目的探讨术后后装放疗加吉西他滨全身化疗对原发性肝癌的治疗效果。方法 1999年10月～2001年12月,将44例行肝癌切除术的原发性肝癌患者随机分为综合治疗组和对照组,每组22例。综合治疗组术中放置施源管3～6根,确定驻留点3～8个,术后3～10天行后装放疗,单次剂量10Gy,照射2～4次,总剂量20～40Gy。放疗结束3周后,开始吉西他滨化疗,静滴1.4g每周1次,4周为1周期,每周期3次,共6个周期。对照组手术后不放、化疗。手术前后定期查血常规、肝功能、AFP、胸片、B 超或 CT。结果综合治疗组后装放疗后 AFP 转阴率100%(17/17),对照组62.5%(10/16)(P<0.05);6月复发率0,低于对照组27.3%(6/22)(P<0.01);综合治疗组1年复发率18.2%(4/22)、转移率0和1年生存率100%(22/22),与对照组的45.5%(10/22)、13.6%(3/22)和77.3%(17/22)均有显著差异(p<0.05)。结论术后后装放疗加吉西他滨全身化疗是提高原发性肝癌近期治疗效果,降低复发率和转移率的有效手段。     

Postoperative day one serum alanine amino-transferase does not predict patient morbidity and mortality after elective liver resection in non-cirrhotic patients

Serum aminotransferases have been used as sur-rogate markers for liver ischemia-reperfusion injury that fol-lows liver surgery. Some studies have suggested that rises in serum alanine aminotransferase (ALT) correlate with patient outcome after liver resection. We assessed whether postopera-tive day 1 (POD 1) ALT could be used to predict patient mor-bidity and mortality following liver resection. We reviewed our prospectively held database and included consecutive adult patients undergoing elective liver resection in our in-stitution between January 2013 and December 2014. Primary outcome assessed was correlation of POD 1 ALT with patient’s morbidity and mortality. We also assessed whether concurrent radiofrequency ablation, neoadjuvant chemotherapy and use of the Pringle maneuver signiifcantly affected the level of POD 1 ALT. A total of 110 liver resections were included in the study. The overall in-hospital patient morbidity and mortality were 31.8% and 0.9%, respectively. The median level of POD 1 ALT was 275 IU/L. No correlation was found between POD 1 serum ALT levels and patient morbidity after elective liver resection, whilst correlation with mortality was not possible because of the low number of mortalities. Patients undergoing concur-rent radiofrequency ablation were noted to have an increased level of POD 1 serum ALT but not those given neoadjuvant chemotherapy and those in whom the Pringle maneuver was used. Our study demonstrates POD 1 serum ALT does not cor-relate with patient morbidity after elective liver resection.     

不可切除中晚期肝癌的转化治疗后肝切除术

多数肝癌起病隐匿，早期症状不明显，就诊时往往已属中晚期，预后不佳。转化治疗可使不可切除晚期肝癌病人获得手术治疗机会，并达到R0切除。在转化治疗后，对病人肿瘤、肝脏及其他器官细致全面的评估，将为安全肝切除的术前决策提供依据。转化治疗期间建议采用多学科综合治疗协作组模式定期评估转化治疗效果，并及时制定手术切除方案。